Short communication: Antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in Zambia

AIDS Research and Human Retroviruses

Volumn 26, Issue 7, 2010, Pages 795-803

  Gonzalez, Sandra ^a   Gondwe, Clement ^b   Tully, Damien C ^a   Minhas, Veenu ^a   Shea, Danielle ^a   Kankasa, Chipepo ^b   M'Soka, Tendai ^b   Wood, Charles ^a  

^a UNIVERSITY OF NEBRASKA   (United States)

^b UNIVERSITY TEACHING HOSPITAL   (Zambia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MARAVIROC; POL PROTEIN; VICRIVIROC; VIRUS DNA; VIRUS ENVELOPE PROTEIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENVELOPE GENE; FEMALE; GENE SEQUENCE; HEALTH CARE AVAILABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; ZAMBIA; ADOLESCENT; ANTIVIRAL RESISTANCE; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; MISSENSE MUTATION; MOLECULAR GENETICS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; SEQUENCE ANALYSIS, DNA; YOUNG ADULT; ZAMBIA;

EID: 77954926298     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0181     Document Type: Article

References (30)

1. WHO: 2008 Report on the global AIDS epidemic Joint United Nations Programme on HIV/AIDS and World Health Organization, 2008.
2. Katzenstein D: Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa. J Infect Dis 2006;194(Suppl 1):S45-S50.
3. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recom-binants in 2004. AIDS 2006;20(16):W13-W23.
4. Cooper ER, Charurat M, Mofenson L, et al.: Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29(5):484-494.
5. Edgeworth RL and Ugen KE: Immunopathological factors for vertical transmission of HIV-1. Pathobiology 2000;68(2): 53-67.
6. Buckton AJ: New methods for the surveillance of HIV drug resistance in the resource poor world. Curr Opin Infect Dis 2008;21(6):653-658.
7. Stringer JS, Zulu I, Levy J, et al.: Rapid scale-up of anti-retroviral therapy at primary care sites in Zambia: Feasibility and early outcomes. JAMA 2006;296(7):782-793.
8. Handema R, Terunuma H, Kasolo F, et al.: Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Res Hum Retroviruses 2003;19(2):151-160.
9. Bessong PO, Mphahlele J, Choge IA, et al.: Resistance mu-tational analysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals. AIDS Res Hum Retroviruses 2006;22(12): 1306-1312.
10. Coman RM, Robbins AH, Fernandez MA, et al.: The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease. Biochemistry 2008;47(2):731-743.
11. Westby M, Smith-Burchnell C, Mori J, et al.: Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007;81(5): 2359-2371.
12. Tsibris AM, Sagar M, Gulick RM, et al.: In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008;82(16):8210-8214.
13. Soto-Ramirez LE, Rodriguez-Diaz R, Duran AS, et al.: Anti-retroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: Plasma versus PBMCs. AIDS Res Hum Retroviruses 2008;24(6):797-804.
14. Zhang H, Orti G, Du Q, et al.: Phylogenetic and phenotypic analysis of HIV type 1 env gp120 in cases of subtype C mother-to-child transmission. AIDS Res Hum Retroviruses 2002;18(18):1415-1423.
15. de Oliveira T, Deforche K, Cassol S, et al.: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005;21(19):3797-3800.
16. Zhang H, Zhou Y, Alcock C, et al.: Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 2004;78(4):1718- 1729.
17. Hall T: BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999;41:95-98.
18. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008;16(1):62-68.
19. Myers RE, Gale CV, Harrison A, Takeuchi Y, and Kellam P: A statistical model for HIV-1 sequence classification using the subtype analyser (STAR). Bioinformatics 2005;21(17): 3535-3540.
20. Gifford RJ, Rhee SY, Eriksson N, et al.: Sequence editing by apolipoprotein B RNA-editing catalytic component-B and epidemiological surveillance of transmitted HIV-1 drug resistance. AIDS 2008;22(6):717-725.
21. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, and Gilks CF: Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008;13(Suppl 2):25-36.
22. Dhami H, Fritz CE, Gankin B, et al.: The chemokine system and CCR5 antagonists: Potential in HIV treatment and other novel therapies. J Clin Pharm Ther 2009;34(2):147-160.
23. Westby M, Lewis M, Whitcomb J, et al.: Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80(10):4909-4920.
24. Tsibris AM, Korber B, Arnaout R, et al.: Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 2009;4(5):e5683.
25. Scarlatti G, Tresoldi E, Bjorndal A, et al.: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-me-diated suppression. Nat Med 1997;3(11):1259-1265.
26. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185(4):621-628.
27. Cilliers T, Nhlapo J, Coetzer M, et al.: The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 2003; 77(7):4449-4456.
28. Ogert RA, Wojcik L, Buontempo C, et al.: Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008; 373(2):387-399.
29. Simen BB, Simons JF, Hullsiek KH, et al.: Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009;199(5):693-701.
30. Cai F, Chen H, Hicks CB, Bartlett JA, Zhu J, Gao F. Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods 2007;4(2):123-125.